Evidence map›Paper›PMID 25533676›Full record

ReviewNature reviews. Cancer2015

VHL, the story of a tumour suppressor gene.

Lucy Gossage, Tim Eisen, Eamonn R Maher

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03979833 (Drivers of Hypoxia-induced Angiogenesis in Tumor Development), which is not on this map. Cited by 467 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
467citing papers in PubMed, 4 pooled it
16.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03979833 unknown statusnot on this mapstarted 2019, after this paper: background citation

Drivers of Hypoxia-induced Angiogenesis in Tumor Development

TypeobservationalSponsorUniversity of CopenhagenRan2019 to 2020Enrolled10ConditionsVon Hippel-Lindau DiseaseArmsWhole exome sequencing
3 · Its place in the literature

Who cites it

467 citing papers in PubMed, 4 syntheses or guidelines pooled it, 775 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Multiplatform curation in the development of ACMG/AMP specifications for Von Hippel-Lindau (VHL) disease.Genetics in medicine : official journal of the American College of Medical Genetics · 2026
    Article
  13. Article
  14. Review
  15. Sandwich therapy combining photodynamic therapy and adjunctive anti-VEGF for juxtapapillary retinal capillary hemangioblastoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  16. Review
  17. Rescuing the Function of Missense-Mutated Tumor SuppressorbioRxiv : the preprint server for biology · 2026
    Article
  18. Article
  19. Article
  20. Article

407 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lucy Gossage1] Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. [2] Department of Oncology, University of Cambridge, Box 193, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. [3] Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
Tim Eisen1] Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. [2] Department of Oncology, University of Cambridge, Box 193, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.
Eamonn R Maher1] Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. [2] Department of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Box 238, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.
Cambridge University Hospitals NHS Foundation Trust · GB

Funding

Cancer Research UK 10868
6 · The paper itself

Abstract

Since the Von Hippel-Lindau (VHL) disease tumour suppressor gene VHL was identified in 1993 as the genetic basis for a rare disorder, it has proved to be of wide medical and scientific interest. VHL tumour suppressor protein (pVHL) plays a key part in cellular oxygen sensing by targeting hypoxia-inducible factors for ubiquitylation and proteasomal degradation. Early inactivation of VHL is commonly seen in clear-cell renal cell carcinoma (ccRCC), and insights gained from the functional analysis of pVHL have provided the foundation for the routine treatment of advanced-stage ccRCC with novel targeted therapies. However, recent sequencing studies have identified additional driver genes that are involved in the pathogenesis of ccRCC. As our understanding of the importance of VHL matures, it is timely to review progress from its initial description to current knowledge of VHL biology, as well as future prospects for novel medical treatments for VHL disease and ccRCC.

Indexed as

Genes, Tumor SuppressorAnimalsBiomarkers, TumorCarcinoma, Renal CellGenetic Association StudiesGenetic Predisposition to DiseaseHumansKidney NeoplasmsMutationvon Hippel-Lindau DiseaseVon Hippel-Lindau Tumor Suppressor ProteinBiomarkers, TumorVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID25533676
OpenAlexW2068919366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.